First Wave BioPharma Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
GRDX$5.35+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Index to Consolidated Financial Statements
| | ||
|---|---|---|
| | Page | |
| | | |
| Report of Independent Registered Public Accounting Firm (Mazars USA LLP, New York, NY, PCAOB ID 339) | | F-2 |
| | | |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | | F-5 |
| | | |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 | | F-6 |
| | | |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023 and 2022 | | F-7 |
| | | |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | | F-9 |
| | | |
| Notes to the Consolidated Financial Statements | | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.